Works by Ko, Eunvin

Results: 7

Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add‐on therapy in drug‐naïve patients with type 2 diabetes (TRIPLE‐AXEL study): A multicentre, randomized, 104‐week, open‐label, active‐controlled trial

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 9, p. 3642, doi. 10.1111/dom.15705

By:

Kim, Nam Hoon;
Moon, Jun Sung;
Lee, Yong‐ho;
Cho, Ho Chan;
Kwak, Soo Heon;
Lim, Soo;
Moon, Min Kyong;
Kim, Dong‐Lim;
Kim, Tae Ho;
Ko, Eunvin;
Lee, Juneyoung;
Kim, Sin Gon

Publication type:

Article

Subthreshold amyloid deposition, cerebral small vessel disease, and functional brain network disruption in delayed cognitive decline after stroke.

Published in:

Frontiers in Aging Neuroscience, 2024, p. 1, doi. 10.3389/fnagi.2024.1430408

By:

Jae-Sung Lim;
Jae-Joong Lee;
Geon Ha Kim;
Hang-Rai Kim;
Dong Woo Shin;
Keon-Joo Lee;
Min Jae Baek;
Eunvin Ko;
Beom Joon Kim;
SangYun Kim;
Wi-Sun Ryu;
Jinyong Chung;
Dong-Eog Kim;
Philip B. Gorelick;
Choong-Wan Woo;
Hee-Joon Bae

Publication type:

Article

Nonhypertensive White Matter Hyperintensities in Stroke: Risk Factors, Neuroimaging Characteristics, and Prognosis.

Published in:

Journal of the American Heart Association, 2023, v. 12, n. 23, p. 1, doi. 10.1161/JAHA.123.030515

By:

Jae-Sung Lim;
Keon-Joo Lee;
Beom Joon Kim;
Wi-Sun Ryu;
Jinyong Chung;
Dong-Seok Gwak;
Ji Sung Lee;
Seong-Eun Kim;
Eunvin Ko;
Juneyoung Lee;
Moon-Ku Han;
Smith, Eric E.;
Dong-Eog Kim;
Hee-Joon Bae

Publication type:

Article

Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin in relation to SLCO1B1 genetic polymorphism.

Published in:

Archives of Pharmacal Research, 2024, v. 47, n. 2, p. 95, doi. 10.1007/s12272-023-01476-9

By:

Cho, Chang-Keun;
Mo, Ju Yeon;
Ko, Eunvin;
Kang, Pureum;
Jang, Choon-Gon;
Lee, Seok-Yong;
Lee, Yun Jeong;
Bae, Jung-Woo;
Choi, Chang-Ik

Publication type:

Article

PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes.

Published in:

Archives of Pharmacal Research, 2024, v. 47, n. 1, p. 82, doi. 10.1007/s12272-023-01478-7

By:

Cho, Chang-Keun;
Ko, Eunvin;
Mo, Ju Yeon;
Kang, Pureum;
Jang, Choon-Gon;
Lee, Seok-Yong;
Lee, Yun Jeong;
Bae, Jung-Woo;
Choi, Chang-Ik

Publication type:

Article

Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects.

Published in:

Archives of Pharmacal Research, 2023, v. 46, n. 2, p. 111, doi. 10.1007/s12272-022-01423-0

By:

Cho, Chang‑Keun;
Byeon, Ji-Young;
Kang, Pureum;
Park, Hye-Jung;
Ko, Eunvin;
Mu, Chou Yen;
Jang, Choon-Gon;
Lee, Seok-Yong;
Lee, Yun Jeong

Publication type:

Article

Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism.

Published in:

Archives of Pharmacal Research, 2022, v. 45, n. 5, p. 352, doi. 10.1007/s12272-022-01388-0

By:

Cho, Chang‑Keun;
Kang, Pureum;
Park, Hye-Jung;
Ko, Eunvin;
Mu, Chou Yen;
Lee, Yun Jeong;
Choi, Chang-Ik;
Kim, Hyung Sik;
Jang, Choon-Gon;
Bae, Jung‑Woo;
Lee, Seok-Yong

Publication type:

Article